Drug Profile
Research programme: targeted platinum theranostics - Nemucore Medical Innovations
Alternative Names: NMI-350Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Nemucore Medical Innovations
- Class Gadolinium-containing contrast agents; Platinum complexes; Radiopharmaceuticals; Sphingolipids
- Mechanism of Action Diagnostic imaging enhancers; DNA cross linking agents; DNA synthesis inhibitors; Folate receptor 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Ovarian-cancer(Diagnosis) in USA (Parenteral)
- 23 May 2016 Preclinical trials in Ovarian cancer (Diagnosis) in USA (Parenteral)